Regarding the mechanism of action and clinical use of antiretroviral drugs, all of the following statements are correct EXCEPT:

Explanation

## Analysis of Antiretroviral Mechanisms ### Correct Statements (Options 0, 1, 3) **Option 0 — Protease Inhibitors (PIs):** - Mechanism: Competitively inhibit HIV protease, preventing cleavage of Gag-Pol polyprotein into functional enzymes and structural proteins - Result: Immature, non-infectious viral particles are released - Examples: Lopinavir/ritonavir, darunavir, atazanavir - ✓ **Correct** **Option 1 — Integrase Inhibitors (INSTIs):** - Mechanism: Block the catalytic activity of HIV integrase, preventing integration of reverse-transcribed viral DNA into the host genome - Result: Viral DNA remains episomal and is diluted out during cell division - Examples: Dolutegravir, raltegravir, elvitegravir - ✓ **Correct** **Option 3 — Nucleoside Reverse Transcriptase Inhibitors (NRTIs):** - Mechanism: Structural analogues of nucleotides; lack 3'-OH group on the ribose (or deoxyribose) sugar - Function: Act as chain terminators during reverse transcription; incorporated into growing DNA chain but prevent further elongation - Examples: Zidovudine (AZT), lamivudine, tenofovir - ✓ **Correct** ### Incorrect Statement (Option 2) — **THE ANSWER** **Option 2 — Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):** - **Common misconception:** NNRTIs are described as "non-competitive inhibitors that bind directly to the active site" - **Actual mechanism:** NNRTIs are **allosteric inhibitors** - They bind to a hydrophobic pocket *adjacent to* (not within) the active site of reverse transcriptase - This allosteric binding induces conformational change that distorts the active site geometry - Result: Substrate cannot bind properly, even though NNRTIs do not occupy the active site - Examples: Efavirenz, rilpivirine, doravirine - ✗ **Incorrect** — the statement incorrectly describes NNRTIs as binding to the active site; they are allosteric, not competitive ### Key Distinction | Drug Class | Binding Site | Inhibition Type | |---|---|---| | NRTIs | Active site (as substrate analogue) | Competitive (chain termination) | | NNRTIs | Allosteric pocket (adjacent to active site) | Allosteric (non-competitive) | | PIs | Active site | Competitive | | INSTIs | Active site of integrase | Competitive | **Key Point:** NNRTIs are **allosteric inhibitors**, not competitive inhibitors of the active site. This distinction is clinically important because: - Resistance mutations in NNRTIs often occur at sites distant from the drug-binding pocket - NNRTIs have a low genetic barrier to resistance (single mutations can confer resistance) - They cannot be used interchangeably with other classes **High-Yield:** The allosteric mechanism of NNRTIs is a frequently tested concept in NEET PG. Students often confuse them with competitive inhibitors; remember: NNRTIs bind *outside* the active site and cause conformational distortion. [cite:Harrison 21e Ch 197]